eGenesis, a Cambridge, MA-based biotechnology company focused on utilizing genome editing technology to enable xenotransplantation* as a routine medical procedure, raised a $38m Series A financing.
The round was co-led by Biomatics Capital and ARCH Venture Partners, with participation from Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America Ltd., Uprising, and Fan Ventures. In conjunction with the funding, Daniel S. Lynch has joined eGenesis as Executive Chairman. Biomatic’s Dr. Boris Nikolic and ARCH’s Dr. Steven Gillis joined the board, as well.
Led by Dr. Luhan Yang, Marc Guell, and seven scientists from Harvard with expertise in genome editing, synthetic biology and transgenic animals, eGenesis is a life sciences company focused on leveraging genome editing technology to deliver effective human transplantable cells, tissues and organs.
It is harnessing its CRISPR-based technology platform to deliver safe and effective human transplantable cells, tissues and organs, which are grown in pigs. This approach is still in its early stages, but includes genomic engineering of pig cells, organ maturation and finally, organ transplantation.
*Xenotransplantation is the process of grafting or transplanting organs or tissues to humans from other species, and it holds vast potential for filling the medical need for healthy organs for transplantation.